Publications
202
Citations
2,095
Est. group size
—
Recurring co-author estimate
Active years
37
Publishing since 1990
Tarah J. Ballinger conducts clinical and translational research on breast cancer, spanning treatment trials (including therapies for HER2-positive and hormone receptor-positive disease), cancer prevention, and survivorship care. Their work also examines how the immune system interacts with breast tumors, particularly in hard-to-treat triple-negative breast cancer, and studies practical issues such as improving patient access to clinical trials and prevention programs. A recurring theme is reducing disparities and helping patients make informed choices about their care.
Publication activity has grown over the decade, rising sharply around 2024, with an average of roughly 31 publications per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Understanding the awareness-to-enrollment gap: An assessment of oncologist barriers in clinical trial accrual.
Journal of Clinical Oncology · 2026
- Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE
JNCI Journal of the National Cancer Institute · 2026
- NCCN Guidelines® Insights: Survivorship, Version 2.2025
Journal of the National Comprehensive Cancer Network · 2025
- Abdominal visceral and subcutaneous adipose tissue associations with postmenopausal breast cancer incidence
JNCI Cancer Spectrum · 2025
- Expression of EZH2 and Fatty Acid Synthase in Breast Tissues From Healthy Women With Breast Cancer Risk Factors
Applied immunohistochemistry & molecular morphology · 2025
- A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer
Clinical Breast Cancer · 2025
- Phase 1 trial of exercise as first-line therapy for hormone receptor (HR)–positive advanced breast cancer (TBCRC 054).
Journal of Clinical Oncology · 2025
- NCCN Guidelines® Insights: Survivorship, Version 2.2024
Journal of the National Comprehensive Cancer Network · 2024
- Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer
Cancer Research Communications · 2024
- Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)
JCO Oncology Practice · 2024
- Disparities in breast cancer prevention initiatives at a comprehensive cancer center: Who are we serving?
Journal of Clinical Oncology · 2024
- Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904)
BMC Medical Informatics and Decision Making · 2024
- Improving communication to increase uptake of high-risk breast cancer prevention appointments: Building a better letter
PEC Innovation · 2024
- Data from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
2024
- Supplementary Figure 5 from NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
2024
- Journal of Clinical Oncology×19
- Medicine & Science in Sports & Exercise×10
- Cancer Research×9
- Journal of the National Comprehensive Cancer Network×5
- Clinical Cancer Research×5
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile